differences appropriately are underway and may help considerably but will not by themselves bring equality. All of these efforts are important and should be prioritized not just for risk prediction but more generally to maximize the use and applicability of genetics to inform on the biology of disease. Given the acute recent attention on clinical use of PRS, we believe it is paramount to recognize their potential to improve health outcomes for all individuals and many complex diseases. Simultaneously, we as a field must address the disparity in utility in an ethically thoughtful and scientifically rigorous fashion, lest we inadvertently enable genetic technologies to contribute to, rather than reduce, existing health disparities.
